Research and Markets (http://www.researchandmarkets.com/research/vcc29x/metastatic) has announced the addition of the "Metastatic Prostate Cancer-Pipeline Insights, 2016" report to their offering.

Metastatic Prostate Cancer-Pipeline Insights, 2016 provides in depth insights on the pipeline drugs and their development activities around the Metastatic Prostate Cancer. The report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration.

Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details.

The report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Metastatic Prostate Cancer.

The report also assesses the Metastatic Prostate Cancer therapeutics by Monotherapy, Combination products, molecule type and Route of Administration.

Scope

  • The report provides competitive pipeline landscape of Metastatic Prostate Cancer
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Metastatic Prostate Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Metastatic Prostate Cancer and also provide company profiling
  • The report also gives the information of dormant and discontinued pipeline projects
  • Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Key Topics Covered:

  1. Metastatic Prostate Cancer Overview
  2. Metastatic Prostate Cancer Pipeline Therapeutics
  3. Metastatic Prostate Cancer Therapeutics under Development by Companies
  4. Metastatic Prostate Cancer Filed and Phase III Products
  5. Comparative Analysis
  6. Metastatic Prostate Cancer Phase II Products
  7. Metastatic Prostate Cancer Phase I and IND Filed Products
  8. Metastatic Prostate Cancer Discovery and Pre-Clinical Stage Products
  9. Metastatic Prostate Cancer - Therapeutics Assessment
  10. Assessment by Monotherapy Products
  11. Assessment by Combination Products
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Metastatic Prostate Cancer - Discontinued Products
  15. Metastatic Prostate Cancer - Dormant Products
  16. Companies Involved in Therapeutics Development for Metastatic Prostate Cancer

For more information visit http://www.researchandmarkets.com/research/vcc29x/metastatic